Roel Bulthuis

Managing Partner
Roel Bulthuis | Inkef
My journey

Roel combines more than 20 years of experience in venture capital, pharma BD and investment banking. Prior to joining Inkef, Roel served as SVP and Managing Director of M-Ventures, which he created and developed into a leading CVC fund. Prior to that, he served in senior positions in global BD at Merck Serono and in the investment banking team at Fortis Bank. Roel holds a Msc. in Biopharmaceutical Sciences from Leiden University and an MBA in Finance from the Helsinki School of Economics. In order to sustain regular open water swimming, cycling and running he cooks a lot of food also.

One fact

I was a very skinny kid and due to the lack of flesh or fat on my bones used to get cold immediately when hitting the water. Every Dutch kid needs to learn to swim and pass their exams but in my case that took several tries and, in the end, only came with the condition that I would join the local water polo club for a few years to gain some strength. On average I swim about 4-6 km per week nowadays and mainly in open water, also in winter. Swimming is the ultimate freedom and the perfect excuse to eat lots of good food.

Ambagon Therapeutics | Inkef

Ambagon Therapeutics applies deep knowledge of the 14-3-3 regulatory protein famiy to create “molecular glues” that stabilize 14-3-3:target complexes. These stabilizers amplify native biology to restore or inhibit target function, potentiate target activity, or promote or block target degradation.

Comet Therapeutics | Inkef

Comet Therapeutics is focused on developing therapies for rare metabolic disorders. It was acquired by VectivBio in 2021.

Ionctura | Inkef

iOnctura is a clinical stage biotechnology company developing a pipeline of next generation, differentiated molecules that are at the forefront of pioneering new therapies for the treatment of cancer. The company is developing a series of assets that can uniquely modulate the tumor micro-environment.

NMD Pharma | Inkef

NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders. Its approach of blocking ClC-1 improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.

Onward | Inkef

ONWARD is creating technologies to improve the movement, independence, and health of people with spinal cord injury. The company is based in Eindhoven, NL and Lausanne, CH and has a growing presence in Boston, US. Two of ONWARD’s technologies have been awarded Breakthrough Device Designation by the FDA. Onward was listed on Euronext in October 2021.

QurAlis | Inkef

QurAlis is developing precision therapeutics for ALS, a terminal disease that causes muscle paralysis through degeneration of the motor system. QurAlis scientist are digging deep into the root causes of the multiple sub-forms of this destructive disease and focus their programs on tackling specific disease-causing mechanisms.

Salvia BioElectronics | Inkef

Salvia Bioelectronics is developing a medical device for chronic headaches. The company is working on a new neuromodulation approach, to provide relief for patients who suffer from debilitating migraines more than 15 days per month.